Chiasma (Chiasma) Total Inventories : $14.38 Mil (As of Mar. 2021)

View and export this data going back to 2015. Start your Free Trial

What is Chiasma Total Inventories?

Chiasma's total inventories for the quarter that ended in Mar. 2021 was $14.38 Mil. Chiasma's average total inventories from the quarter that ended in Dec. 2020 to the quarter that ended in Mar. 2021 was $12.67 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Chiasma's Net-Net Working Capital per share for the quarter that ended in Mar. 2021 was $0.45.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chiasma's Days Inventory for the three months ended in Mar. 2021 was 17,253.06.

Inventory Turnover measures how fast the company turns over its inventory within a year. Chiasma's Inventory Turnover for the quarter that ended in Mar. 2021 was 0.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chiasma's Inventory-to-Revenue for the quarter that ended in Mar. 2021 was 6.58.

Chiasma Total Inventories Historical Data

The historical data trend for Chiasma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma Total Inventories Chart

Chiasma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Inventories

Get a 7-Day Free Trial

10.96

Chiasma Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Inventories	Get a 7-Day Free Trial															-	-	8.94	10.96	14.38

Chiasma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Chiasma (NAS:CHMA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Chiasma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2021 is

	Net-Net Working Capital Per Share (Q: Mar. 2021 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(115.033	+	0.75 * 1.015	+	0.5 * 14.381	-	96.847
-	0	-	0)	/	57.8436
=	0.45

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chiasma's Days Inventory for the three months ended in Mar. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2021 )	/	Cost of Goods Sold (Q: Mar. 2021 )	*	Days in Period
	=	12.668	/	0.067	*	365 / 4
	=	17,253.06

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Chiasma's Inventory Turnover for the quarter that ended in Mar. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2021 )	/	Average Total Inventories (Q: Mar. 2021 )
	=	0.067	/	12.668
	=	0.01

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chiasma's Inventory to Revenue for the quarter that ended in Mar. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2021 )	/	Revenue (Q: Mar. 2021 )
	=	12.668	/	1.924
	=	6.58

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Chiasma Total Inventories Related Terms

Thank you for viewing the detailed overview of Chiasma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiasma (Chiasma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Kendrick Street, Building C East, Needham, MA, USA, 02494

Website

https://www.chiasmapharma.com

Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.

Executives

Roni Mamluk	director	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack	director	THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman	director	C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick	director	C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan	officer: EVP, Chief Commerical Officer	C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere	officer: General Counsel	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam	officer: See Remarks	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait	officer: VP, Fin & Admin, PAO	C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick	officer: President	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116